Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.

Journal: Cancer
Published:
Authors
Mary Nierengarten

Similar Publications

We couldn’t find any related articles. Please check for more on the main search page.
View All